1. Introduction
===============

Lung cancer remains to be one of the leading causes of cancer-related mortality around the world despite the development in treatment strategies of lung cancer.^\[[@R1],[@R2]\]^ In 2016, the number of patients suffering from lung cancer or bronchial cancer will increase by 224,390, including 117,920 in men and 106,470 in women in the United States.^\[[@R3]\]^ In addition, most patients are generally diagnosed at an advanced and metastatic stage, often accompanied by poor prognosis and difficult-to-manage disease. Generally, lung cancer can be divided into 2 categories: small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC) which further includes 2 subdivisions (squamous and nonsquamous NSCLC).

For the early-stage lung cancer, local treatment strategies include surgical resection and definitive radiation. For the advanced cases, however, a multimodality strategy should be employed, and systemic therapy will be the principal treatment for metastatic disease. Cytotoxic and platinum doublet-based chemotherapy has been selected as the first-line treatment for patients with metastatic NSCLC, and a considerable median survival of 8 to 12 months was obtained.^\[[@R4]--[@R6]\]^ Docetaxel was approved as the second-line treatment for patients based on 2 phase 3 trials.^\[[@R7]--[@R9]\]^ Also, an improved response rate was observed in most NSCLC patients treated with first-line chemotherapy; however, the disease progressed rapidly during or after the treatment, and the clinical efficacy of second-line chemotherapy was unsatisfactory either.

Recently, the novel therapy based on the immune checkpoints exhibits significant potential in treatment of patients with advanced NSCLC and SCLC.^\[[@R1],[@R10],[@R11]\]^ Programed death 1 (PD-1) is a vital immune checkpoint receptor which is expressed on activated T cells.^\[[@R12]\]^ Normally, the interaction between PD-1 and programed death ligand 1 (PD-L1) will lead to the inhibition of immune response,^\[[@R13]\]^ thus preventing the excessive inflammation. Otherwise, PD-L1 was also found to be expressed in some tumor cells including those of NSCLC.^\[[@R14]\]^ Activated T cells that target the tumor cells will be inactivated by interaction of PD-1 and PD-L1, ultimately allowing tumor progress and metastasis. Therefore, blocking the PD-1 pathway by disrupting the binding of PD-1 to its ligand will provide an effective approach for recovering the antitumor immunity mediated by T cells. Up to now, several monoclonal antibodies targeting PD-1 or PD-L1 have already been developed. Nivolumab is a fully humanized Immunoglobulin G (IgG4) antagonist monoclonal antibody targeting PD-1 and is approved by the United States Food and Drug Administration for treatment of NSCLC. Findings of several single-arm and multiarm studies indicated an improved overall survival (OS) and response rate in advanced NSCLC patients when treated with nivolumab as monotherapy or combination with other chemotherapy.^\[[@R15],[@R16]\]^ Pembrolizumab is another humanized IgG4 antagonist antibody against PD-1.^\[[@R17]\]^ A phase 2/3 study about pembrolizumab reported a better OS in patients treated with pembrolizumab than that of patients administrated with docetaxel.^\[[@R18]\]^ Atezolizumab is an anti-PD-L1 antibody, an assessment concerning the efficacy and safety of atezolizumab versus docetaxel in patients with previously treated NSCLC was performed by Fehrenbacher et al,^\[[@R19]\]^ the results exhibited a more considerable survival in atezolizumab-treated arm than docetaxel. Based on the study results of nivolumab, pembrolizumab, and atezolizumab, the anti-PD-1/PD-L1 therapy exerts as a highly promising treatment paradigm in patients with advanced NSCLC. However, the adverse effects potentially caused by PD-1/PD-L1 therapies cannot be ignored, which has been previously reported in several studies. This article is a meta-analysis aiming to further evaluate the efficacy and safety of anti-PD-1/PD-L1 agents in advanced NSCLC patients, subgroup analysis was also performed to figure out the efficacy among patients with different epidermal growth factor receptor (EGFR) status.

2. Method
=========

2.1. Search strategy
--------------------

A comprehensive search for studies published in English was performed in the PubMed, ScienceDirect, and Web of Science in order to collect all relevant citations. The date of the last search was May 20, 2016. Meeting abstracts from Major European and American oncology meetings were also evaluated. Keywords for studies search were as follows: "non small cell lung cancer" OR "NSCLC" AND "nivolumab" OR "pembrolizumab" OR "atezolizumab" OR "Opdivo" OR "BMS-936558" OR "MDX1106" OR "MK-3475" OR "lambrolizumab" OR "MPDL3280A".

2.2. Selection criteria
-----------------------

Inclusion criteria are the followings: articles that evaluate anti-PD-1/PD-L1 agents in treatment of patients with NSCLC, articles with or without report of PD-L1 expression level will be included; studies including 1 or all of the following information: objective response rate (ORR), OS, and progression-free survival (PFS). Letters, editorials, expert opinions, case reports, duplicate publications, and reviews should be excluded as well as the studies without usable data.

2.3. Data extraction
--------------------

Data were extracted independently by 3 authors from eligible studies. The following data were collected: authors, treatment strategy, number of patients, ORR, PFS, OS, adverse effect events, or frequency.

2.4. Outcome measures
---------------------

The outcome measures were ORR, PFS, and OS. This systematic review follows the guidelines provided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Report (PRISMA statement).^\[[@R20]\]^

2.5. Data analysis
------------------

For ORR, odds ratio (OR) and corresponding 95% confidence intervals (CIs) are the principal summary measures, while for PFS and OS, hazard ratios (HRs) and corresponding 95% CIs are the principal measures. Relevant data were extracted from each study, and the pooled ORs and HRs were estimated through a meta-analysis. Fixed effects model will be used in the analyses if there is no substantial heterogeneity among different studies, or the random effects model will be applied. All analyses were conducted using the program RevMan5.3 (Nordic Cochrane center, Copenhagen, Denmark). For single-arm or noncontrolled studies, the pooled ORR, 1-year progression-free survival rate, and 1-year OS rate will be estimated by MetaAnalyst 3.13 (Boston, MA, USA). Heterogeneity will be assessed with the Chi^2^ testing and *I*^2^ statistic, *P* value less than 0.05 indicates significant heterogeneity, *I*^2^ value greater than 50% is considered significant heterogeneity. The publication bias will be assessed using funnel plots.

3. Results
==========

3.1. Search results and characteristics of included studies
-----------------------------------------------------------

The PRISMA diagram for the study selection is summarized in Fig. [1](#F1){ref-type="fig"}. A total of 466 results were obtained from the searches in PubMed, 1563 from ScienceDirect, and 547 from web of science. A total of 2352 studies were excluded for duplication and 238 for not meeting the eligibility criteria in the initial selection. After the full-text search, 9 studies involving 2 phase 1 trials,^\[[@R21],[@R22]\]^ 3 phase 2 trials,^\[[@R19],[@R23],[@R24]\]^ 4 phase 3 trials^\[[@R18],[@R25]--[@R27]\]^ were included in the following analysis. Six studies assessed nivolumab, 2 assessed pembrolizumab, and 1 assessed atezolizumab. Four studies compared the efficacy and safety of PD-1/PD-L1 agents with doectaxel, 5 studies evaluated efficacy and safety of PD-1/PD-L1 alone. A total of 3032 patients were included in this analysis. PD-1/PD-L1 agents were administrated as monotherapy in all included studies, different dose settings were found in 3 studies. Detailed treatment strategies are summarized in Table [1](#T1){ref-type="table"}.

![Flowchart of study selection procedure.](medi-95-e5539-g001){#F1}

###### 

Efficacy outcomes in included studies.
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3.2. Efficacy outcomes of PD-1/PD-L1 agents versus docetaxel
------------------------------------------------------------

### 3.2.1. Overall survival, progression-free survival, and objective response rate

Four studies assessed the efficacy and safety of PD-1/PD-L1 agents versus docetaxel in patients with advanced NSCLC. Three studies were 2-arm trials,^\[[@R19],[@R25],[@R26]\]^ the other one was a 3-arm trial including a different dose setting of pembrolizumab.^\[[@R18]\]^ The pooled HR for OS was 0.68 (95% CI 0.61--0.75; *P* \< 0.001) (Fig. [2](#F2){ref-type="fig"}A). The pooled OR for ORR was 1.83 (95% CI 1.41--2.36; *P* \< 0.001) (Fig. [2](#F2){ref-type="fig"}C). Since the PFS was not available in 1 study, the pooled HR for PFS was estimated with 3 studies only. The pooled HR for PFS was 0.83 (95% CI 0.75--0.91; *P* \< 0.001) (Fig. [2](#F2){ref-type="fig"}B). Thus, the analysis suggested a significant benefit from anti-PD-1/PD-L1 therapies in treatment of patients suffering from advanced NSCLC when compared with docetaxel.

![Pooled hazard ratio for overall survival (A), progression-free survival (B), and pooled odds ratio for objective response rate (C) in patients treated with programed death 1/programed death ligand 1 agents versus docetaxel. ∗ Represents an arm treated with pembrolizumab 10 mg/kg in Ref. ^\[[@R18]\]^.](medi-95-e5539-g003){#F2}

### 3.2.2. EGFR affects the benefits from anti-PD-1/PD-L1 therapies

We observed that both Herbst and Borghaei reported the subgroup analysis of OS stratified by EGFR status. Here, we also analyzed the different efficacy of PD-1/PD-L1 agents among patients tested with different EGFR status. Finally, the HR values with 1.05 (95% CI 0.69--1.59; *P* = 0.81) and 0.66 (95% CI 0.57--0.77; *P* \< 0.001) were obtained in patients with mutant and wild-type EGFR status, respectively (Fig. [3](#F3){ref-type="fig"}).

![Subgroup analysis of overall survival in patients with different epidermal growth factor receptor status.](medi-95-e5539-g004){#F3}

3.3. Efficacy outcomes of PD-1/PD-L1 agents when employed as monotherapy
------------------------------------------------------------------------

Nine studies include available data of ORR, the overall ORR was 18.7% (95% CI 17.0--20.4). Four researches reported that the 1-year OS and 1-year program-free survival with the pooled value were 42.3% (95% CI 38.5--46.1) and 20.1% (95% CI 17.3--23.2), respectively (Fig. [4](#F4){ref-type="fig"}).

![Overall 1-year overall survival (A), 1-year progression-free survival (B), and ORR (C) in patients administrated with programed death 1/programed death ligand 1 agents as monotherapy.](medi-95-e5539-g005){#F4}

3.4. Safety assessment
----------------------

Treatment-related adverse effect is an important evaluation index for any antitumor therapies. Many treatments have to be discounted for the severe adverse effects caused by the treatment agents. To evaluate the safety of PD-1/PD-L1 agents in advanced NSCLC patients, data of the total adverse effect events and grade 3 to 5 adverse effect events were collected and analyzed. The OR of the total adverse effect events for patients receiving PD-1/PD-L1 agents versus docetaxel was 0.36 (95% CI 0.28--0.46; *P* \< 0.001), and the OR of grade 3 to 5 adverse effect events was 0.18 (95% CI 0.14--0.22; *P* \< 0.001) (Fig. [5](#F5){ref-type="fig"}). On the basis of the observed results, it was indicated that the incidence of treatment-related adverse effect caused by PD-1/PD-L1 agents was significantly lower than that caused by docetaxel.

![Pooled odds ratio for incidence of any grade treatment-related adverse effect (A) and grade 3 to 5 treatment-related adverse effect (B).](medi-95-e5539-g006){#F5}

4. Discussion
=============

Rapid progression during or after the standard chemotherapy in patients with NSCLC indicates that a new effective treatment diagram is in urgent need. PD-L1 has been demonstrated to be a tumor-related biomarker contributing to tumor advance. The binding of PD-1 expressed by activated T cells to PD-L1 induces the immune suppression, thus protecting the normal cells from being attacked by active T cells. Previous researches have found that some tumor cells can evade immune recognition via expressing PD-L1, which provided a potentially effective antitumor strategy. Monoclonal antibodies targeting PD-1 or PD-L1, like nivolumab, pembrolizumab, and atezolizumab, can restore the antitumor effect of T cells by blocking the PD-1 signal. An improvement in OS and PFS as well as lower incidence of treatment-related adverse effect was previously reported in several phase 2 and phase 3 trials focusing on PD-1/PD-L1 antibodies. To further validate this immune checkpoint therapy, the effect and safety of PD-1/PD-L1 agents in NSCLC patients were systematically analyzed in this article.

In this study, we first compared the efficacy of PD-1/PD-L1 agents with docetaxel in advanced NSCLC patients. OS and progression-free survival were selected as the primary endpoints, ORR was the second endpoint. According to the pooled HR values, patients administrated with nivolumab, pembrolizumab, or atezolizumab had a better OS and PFS than those who were treated with docetaxel. The pooled OR also suggested a higher ORR with 14.6% to 20.0% in PD-1/PD-L1 therapy group across the studies containing a docetaxel control, the reported median OS in patients with PD-1/PD-L1 agents administration was 9.2 to 12.7 months, which was longer than that in docetaxel-treated group (7.3--9.7 months), while the median progression-free survival was 2.3 to 4.0 months in PD-1/PD-L1 agents administration cohort and 2.8 to 4.2 in docetaxel-treated cohort. Hence, it was concluded that the PD-1/PD-L1 therapy significantly improved the OS and ORR rather than the progression-free survival when compared to docetaxel. It was reported that progression-free survival with pembrolizumab was superior to that of docetaxel in NSCLC patients with a tumor proportion score of \>50%, but not in the total population, while OS with pembrolizumab was superior to that of docetaxel in total population. Here, the slight improvement of PD-1/PD-L1 agents on progression-free survival may be ascribed to the different tumor proportion score.^\[[@R18]\]^

Considering that the PD-L1 is the key target of the PD-1/PD-L1 therapy, the expression level of PD-L1 in tumor cells may presumably impact the efficacy of PD-1/PD-L1 therapy. Several recent trials demonstrated that PD-L1 expression had a significant correlation with OS, ORR, and PFS. A further meta-analysis pointed out that the benefit from PD-1/PD-L1 therapy versus docetaxel as second-line treatment in NSCLC patients was only limited to subpopulation with a PD-L1 expression level of \>1%.^\[[@R28]\]^ Not only the PD-L1 expression level but also the EGFR status and smoking history can affect the benefits from PD-1/PD-L1 therapy,^\[[@R25]\]^ which has been reported in previous studies. Here, we conducted a subgroup analysis to clarify the different efficacy in NSCLC patients with different EGFR status. The results showed a significant improvement in OS of patients with wild-type EGFR; nevertheless, the same results were not observed in patients with mutant EGFR. An immunohistochemical analysis in 164 specimens of surgically resected NSCLC was conducted by Azuma et al,^\[[@R29]\]^ the results of a multivariate analysis revealed that the presence of EGFR mutant was significantly associated with a higher PD-L1 expression level. In addition, patients with higher PD-L1 expression had a shorter OS, which was contrary to the results reported by Abdel-Rahman.^\[[@R28]\]^ Taking into accounting of the above facts, the inherent relationship among PD-L1 expression, EGFR status, and benefits from PD-1/PD-L1 therapy was more complicated than we imaged. The role of EGFR status as well as PD-L1 expression level as a potential predictive biomarker for decision-making about treatment strategy in clinic need to be further discussed. As to the smoking history, patients who are current or former smoker experienced a significant benefit from PD-1/PD-L1 therapy. An HR value of 0.70 (95% CI 0.56--0.86) for OS was reported in a subpopulation with a smoking history in a phase 3 trial, while the HR value in patients never smoking was 1.02 (95% CI 0.64--1.61).^\[[@R25]\]^ In another study, the author reported a numerically higher ORR among patients with smoking history.^\[[@R22]\]^ A subgroup analysis was not performed here to systematically compare the efficacy of PD-1/PD-L1 therapy between smoking and nonsmoking patients, because the reported endpoint varied across the included studies. On account of limited trials toward the relationship between efficacy of PD-1/PD-L1 therapy and smoking history, the observed better efficacy in smoking patients needs to be further confirmed.

The safety profile of PD-1/PD-L1 therapy was also evaluated in this article. The reported treatment-related adverse effects include decreased appetite, fatigue, nausea, rash, diarrhea, asthenia, stomatitis, anemia, alopecia, and neutropenia.^\[[@R18]\]^ The pooled OR was 0.36 for any grade adverse effects and 0.18 for grade 3 to 5 adverse effects, this indicated a protective role of PD-1/PD-L1 agents in NSCLC patients versus docetaxel. The superiority of PD-1/PD-L1 therapy versus docetaxel in the treatment of NSCLC patients was more notable when we turned our attention to neutropenia, febrile neutropenia, leukopenia, and alopecia of which a significantly lower incidence was observed in PD-1/PD-L1 agents treatment group. Fatigue is a common treatment-related adverse effect with a higher frequency than others, a meta-analysis performed by Abdel-Rahman et al^\[[@R30]\]^ demonstrated that a lower risk of all grade fatigue, compared with control regimens, was possibly ascribed to PD-1 inhibitors. However, the high incidence of pneumonitis, hypothyroidism, and hyperthyroidism observed in pembrolizumab group cannot be ignored, whereas it was lower in docetaxel group. In a recently published research, the side effects caused by anti-PD-1 therapy were summarized.^\[[@R31]\]^ Thus, a careful consideration against potential toxicities caused by PD-1/PD-L1 agents is necessary when PD-1/PD-L1 therapy is employed. In most studies included in this analysis, PD-1/PD-L1 inhibitors were employed as monotherapy, but the studies focusing on efficacy of its combination with chemotherapies or other target therapies were limited. The ORR between 33% and 47% were obtained in a study evaluating the effect of nivolumab in combination with platinum-based doublet chemotherapy,^\[[@R15]\]^ it proved that PD-1/PD-L1 agents in combination with other therapies may exert as a promising therapy diagram, especially in NSCLC patients experiencing progression after several lines of therapy.

5. Conclusion
=============

In conclusion, our analysis revealed that PD-1/PD-L1 agents significantly prolonged the OS and increased the ORR when compared to docetaxel, while more data are needed to confirm whether the PD-1/PD-L1 therapy is superior when challenging to other standard chemotherapies. The better benefits from PD-1/PD-L1 agents observed in patients with wild-type EGFR were controversial, more efforts are required to understand the real relationship between PD-1/PD-L1 efficacy and EGFR status. Based on the analysis of adverse effect, a lower risk was associated with the PD-1/PD-L1 therapy versus docetaxel, while the occurrence of related side effects like pneumonitis and endocrine dysfunction deserves more attention.

Abbreviations: CI = confidence interval, EGFR = epidermal growth factor receptor, HR = hazard ratio, NSCLC = nonsmall cell lung cancer, OR = odds ratio, ORR = objective response rate, OS = overall survival, PFS = progression-free survival, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis.
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